Associated Papers
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Tantawy SI et al.
Blood Cancer Journal, 2025
In Silico Investigation of BTK as a Potent Immunomodulatory Target: Exploring Novel Therapeutic Approaches for Multiple Sclerosis.
Saba A et al.
Acs Omega, 2025
Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
Gruessner C et al.
Leukemia & Lymphoma, 2025
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.
Garcia M et al.
Annals of Hematology, 2025
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.
Brown JR et al.
Blood Advances, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.
Gandhi V et al.
Research Square, 2025
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Elife, 2024
Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
Joseph RE et al.
Biorxiv : the Preprint Server for Biology, 2024
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
Song PR et al.
Acta Pharmacologica Sinica, 2024
Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib.
Woyach JA et al.
Blood, 2024
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
Pozzo F et al.
Leukemia, 2024
Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.
Wong RL et al.
Leukemia, 2024
The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas.
Mehra S et al.
International Journal of Molecular Sciences, 2024
BTK inhibitors in CLL: second-generation drugs and beyond.
Tam C et al.
Blood Advances, 2024
A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Wiśniewski K et al.
International Journal of Molecular Sciences, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S et al.
Science (new York, N.y.), 2024
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
Brown J et al.
Research Square, 2024
Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).
Chirino A et al.
Genes, 2023
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Qi J et al.
Blood Advances, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.
Woyach JA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma.
Tatarczuch M et al.
Blood Advances, 2023
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA et al.
Blood Advances, 2023
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S et al.
Blood Advances, 2023
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A et al.
Blood Advances, 2023
Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.
Lim YS et al.
Blood Advances, 2023
BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma.
Yuan H et al.
The Journal of Biological Chemistry, 2022
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blombery P et al.
Blood Advances, 2022
Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
Dhami K et al.
Science Signaling, 2022
Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.
Aslan B et al.
Blood Cancer Journal, 2022
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Thompson ER et al.
Blood Advances, 2022
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
Maffei R et al.
Leukemia & Lymphoma, 2021
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Estupiñán HY et al.
Leukemia, 2021
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Hamid AB et al.
Cancers, 2020
Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents.
Sedlarikova L et al.
Frontiers in Oncology, 2020
The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study.
Punta M et al.
Frontiers in Immunology, 2020